<DOC>
	<DOCNO>NCT02499848</DOCNO>
	<brief_summary>To Evaluate Safety , Tolerability Potential Efficacy PRX302 effect clinically significant localise low intermediate prostate cancer .</brief_summary>
	<brief_title>Evaluate , Safety Tolerability Intraprostatic PRX302 Administration , Low Intermediate Risk Prostate Cancer</brief_title>
	<detailed_description>A single center , open label , Phase IIa , Idea , Development , Exploration , Assessment , Long-term follow-up ( IDEAL ) prospective development study . The study treat approximately 20 men meet eligibility criterion , give write informed consent . Safety Tolerability assess post-treatment 2 day ( phone call ) , 2 week , 6 week , 12 week , 24 week 26 week . Potential Efficacy assess biopsy 24 week image ( MRI ) 2 week , 12 week 24 week PSA outcomes 12 24 week .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Men age ≥40 year life expectancy ≥10 year . Serum prostatespecific antigen ( PSA ) ≤15 ng/mL . Transperineal prostate biopsy within 12 month prior dose , clinically significant lesion correlate mpMRI visible lesion . Radiological stage T1T2 N0 Mx/M0 disease . A visible lesion mpMRI accessible PRX302 transperineal injection . Previous radiation therapy pelvis . Androgen suppression antiandrogen therapy within 12 month prior dose , prostate cancer . Use 5alpha reductase inhibitor within 3 month prior dose . Evidence metastatic disease nodal disease outside prostate bone scan crosssectional imaging . Inability tolerate transrectal ultrasound ( TRUS ) . Known allergy latex gadolinium ( Gd ) . Previous electroporation , radiofrequency ablation , highintensity focus ultrasound ( HIFU ) , cryosurgery , thermal microwave therapy treat cancer prostate . Unable pelvic MRI scanning ( severe claustrophobia , permanent cardiac pacemaker , metallic implant , etc . likely contribute significant artifact image ) .</criteria>
	<gender>Male</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>MRI Lesion</keyword>
	<keyword>transperineal injection</keyword>
	<keyword>prostate biopsy</keyword>
</DOC>